Member Info for Lp160606

SNG is not punt.

Already proven in COPD patients. Chinese suggested usage of interferon x2 per day via injection to alleviate Covid-19.
https://www.fip.org/files/content/priority-areas/coronavirus/CPA-CORONAVIRUS-2019-nCoV-Expert-Consensus-on-Guidance-and-Prevention.pdf

That link is dated February. They knew it worked and then started utilizing an inhaled version via cuban biotech company alongside Dr hernandez - http://www.academiaciencias.cu/en/node/545

Inhaler higher efficacy as is it delivered straight the lungs and mitigates side affects seen in interferon injections.

150k but after hours in the middle of a medical trial.

Not a coin toss.

Taff, listened through. Can hear him mentioning add zinc. Is this what you're referring too?

No clear mention of sng. But hoping I'm wrong

Personally believe it will start strong. Slight late morning/early afternoon retrace. And close high 60s.

This will become highly traded as we get closer to results, expect turbulence.

On the opinion piece mate, dont worry about that. We all chat nonsense on these boards at the best of time. Sometimes it is nice to get a buzz about a share.

And there is definitely a buzz around this one!

Does not actually state what it is.

However, it is at the same price as a buy that took place after hours also. So would suggest that is a Buy.

UT of 12k in late auction.

Beginning to really hot up.

Cool. Thanks Technick.

What is GDR test turnaround times?

Hi Ghia,

Have you seen this Chinese medical extract advising for the use of Interferon in relation to Covid. listed as a KEY treatment. My only concern with the trial is that it seems Interferon was used along side others and that perhaps alone it will not deliver the conclusive results needed.

https://www.fip.org/files/content/priority-areas/coronavirus/CPA-CORONAVIRUS-2019-nCoV-Expert-Consensus-on-Guidance-and-Prevention.pdf

Nice Mike. keep us posted.

Spread was 57 - 57.5 not long ago...

Pilgrim.. current MC of 70M .. Madness.

No live quote available on HL

lol could it of been

Thank Mike.

You too!

Yeh, moved everything from NCYT to this.

Moved it too early but there are.

wow. Intense reading that.

This is from the Drs bio.. would he be aware of Synairgen? You would think so.

Previously, Dr Leach was Clinical Director for Acute Medicine from 2009-18. In the GSTT and Medway Foundation Trust (MFT) support collaboration he was an Associate Medical Director at MFT from 2015-18.
Dr Leach is on the European Specialist Registers for General (Internal), Respiratory and Critical Care Medicine and has extensive experience as a general and respiratory physician contributing to both high dependency and intensive care medicine. He has sub-specialty interests in COPD, asthma, cough, respiratory failure, sarcoidosis, multiple co-morbidity conditions and critical care medicine.

I have taken comfort from this, we are in the midst of a medical trial and yet we have a proof point of a very similar drug being utilized in patients as a KEY treatment.

Please note this was released at the beginning of February. Bloody crazy actually, but i am sure their approach developed somewhat into using the bio tech company from Cuba.

The point is, this is a proof point. Not a write up in the newspaper.

As with SGD i could never try to distinguish between interferon a or b. But the material i am consuming suggests that ours is a safer/more effective way to administer as is direct to the lung, and does not harbor the side effects of the injection.

Apologies for the formate of the below but it is a must read... We are the first suggested treatment ont the least as anti viral. I know it is not Interferon B, but it is of the same family.

Knew it would be somewhere. - https://www.fip.org/files/content/priority-areas/coronavirus/CPA-CORONAVIRUS-2019-nCoV-Expert-Consensus-on-Guidance-and-Prevention.pdf

3 Treatment
3.1 Characteristics and precautions of treatment options
At present, there is no targeted antiviral treatment for the 2019-nCoV infection. The
Coronavirus 2019-nCoV Infection: Expert Consensus on Guidance and Prevention Strategies for hospital
pharmacists and the pharmacy workforce (1
st Edition)
4
following drugs may be used in clinical practice and clinical trials. Due to ongoing
studies, pharmacists should track the latest research evidences and updates. Pay
attention to the risk of off-label usage under special circumstances.
3.1.1 Interferon[1]
May try inhaling aerosolized interferon, 5 million IU for adults, adding 2mL of
sterilized water for injection, twice a day. Common adverse reactions include fever,
fatigue, headache, joint pain, loss of appetite, etc. Noting that patients with a history
of antibiotic allergy should use with caution. The administration of first dose should
be closely monitored. Be careful to avoid contact with eyes during atomization. Store
at 2-8? and protect from light during storage and transportation.

Function Drug name Dosage form and
specifications[41] References
Antiviral
treatment
Recombinant Human
Interferon
Recombinant Human
Interferon a-1b
Injection: 10µg: 0.5mL,
30µg: 1mL;
Recombinant Human
Interferon a-2a
Injection, Recombinant
Human Interferon a-2a
Injection: 3 million IU,

Made me laugh that. Dillon has no TV, yet has invested in ITV.

Great bit of exposure this though!

Some random 50 year old trump supporting american tweeting about Synairgen isn't really worth of news mate.